• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Chinese expert consensus on diagnosis and treatment of high risk multiple myeloma (2024)

by | Jul 5, 2024 | Publications

Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):430-435. doi: 10.3760/cma.j.cn121090-20240312-00090. ABSTRACT High-risk multiple myeloma (HRMM) refers to patients with multiple myeloma whose overall survival time is less than 2-3 years under current standardized...

Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy

by | Jul 5, 2024 | Publications

Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):436-444. doi: 10.3760/cma.j.cn121090-20240131-00047. ABSTRACT Objective: To construct a novel chimeric antigen receptor T (CAR-T) cell targeting CD138 and to investigate its cytotoxicity against myeloma cells. Methods: The...

Correlation analysis of polyclonal plasma cell proportion in the bone marrow with clinical characteristics of patients with newly diagnosed multiple myeloma

by | Jul 5, 2024 | Publications

Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):475-480. doi: 10.3760/cma.j.cn121090-20231020-00221. ABSTRACT Objective: To explore the correlation of bone marrow polychonal plasma cell proportion (pPC% ) and clinical features in newly diagnosed multiple myeloma (NDMM)...

Retrospective clinical study on cryopreservation-free integrated autologous hematopoietic stem cell transplantation model for newly diagnosed multiple myeloma

by | Jul 5, 2024 | Publications

Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):488-494. doi: 10.3760/cma.j.cn121090-20230929-00152. ABSTRACT Objective: To explore the efficacy and safety of cryopreservation-free integrated autologous hematopoietic stem cell transplantation (HSCT) model for patients...

Gastric and colic digestive localizations of myeloma; 3 case studies and literature review

by | Jul 5, 2024 | Publications

Ann Pathol. 2024 Jul 3:S0242-6498(24)00129-9. doi: 10.1016/j.annpat.2024.06.007. Online ahead of print. ABSTRACT Multiple myeloma is a malignant plasma cell proliferation located in the bone marrow and bones. It can secondarily manifest with extraosseous involvement,...

Clotrimazole inhibits growth of multiple myeloma cells in vitro via G0/G1 arrest and mitochondrial apoptosis

by | Jul 5, 2024 | Publications

Sci Rep. 2024 Jul 4;14(1):15406. doi: 10.1038/s41598-024-66367-5. ABSTRACT Patients with multiple myeloma (MM) experience relapse and drug resistance; therefore, novel treatments are essential. Clotrimazole (CTZ) is a wide-spectrum antifungal drug with antitumor...
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • Multiple myeloma incidence, transplant utilization, and mortality- impact of social vulnerability
  • Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
  • Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis
  • Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma
  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT